stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) EV/FCF
As of 6 November 2026, Dianthus Therapeutics, Inc. (DNTH) trades at a EV/FCF of −23.4×. Over the past ten years it has ranged from −36.0× (August 2026) to 9.1× (September 2023); the current reading is higher than 5% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −9.2× | — |
| FY2024 | −5.8× | — |
| FY2023 | 3.1× | 29.93% |
| FY2022 | 2.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −23.9× | — |
| Jun 2026 | −29.4× | — |
| Mar 2026 | −22.4× | — |
| Dec 2025 | −9.2× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MANE Veradermics Incorporated compare | −38.8× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −30.6× |
| DNTH Dianthus Therapeutics, Inc. | −23.4× |
| ERAS Erasca, Inc. compare | −16.6× |
| DFTX Definium Therapeutics, Inc. compare | −15.7× |
| COGT Cogent Biosciences, Inc. compare | −15.6× |
| EWTX Edgewise Therapeutics, Inc. compare | −15.5× |
| CRSP CRISPR Therapeutics AG compare | −8.3× |
| TVTX Travere Therapeutics, Inc. compare | 56.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement